(RTTNews) - Lisata Therapeutics (LSTA) has acquired Marea Therapeutics, a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop next-generation medicines for cardioendocrine diseases. The acquisition was structured as a stock-for-stock transaction pursuant to which all of Marea's outstanding equity interests were exchanged based on a fixed exchange ratio for a combination of 1,793,129 shares of Lisata common stock and 211,365.213 shares of Series C non-voting convertible preferred stock. Marea Therapeutics' lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia. The company is also advancing MAR002 for the treatment of acromegaly.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。